Followers | 4053 |
Posts | 151407 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Thursday, September 29, 2022 12:50:37 AM
CONGRAT$ to anyone making $$
Recent ABOS News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:35:38 AM
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 09:47:25 PM
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights • GlobeNewswire Inc. • 03/26/2024 11:00:00 AM
- Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 • GlobeNewswire Inc. • 03/19/2024 08:00:00 PM
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days • GlobeNewswire Inc. • 03/12/2024 08:00:00 PM
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 03/08/2024 01:50:00 PM
- Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:32:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:02:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:01:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:16:51 PM
- Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer • GlobeNewswire Inc. • 02/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:07:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:06:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:05:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:05:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:04:18 AM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM